Human Pathology
Volume 41, Issue 2 , Pages 223-231 , February 2010

Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project

  • Roberto Fiocca, MD

      Affiliations

    • Department of Anatomic Pathology, University of Genoa, Genoa, Italy
    • Corresponding Author InformationCorresponding author. Division of Anatomical Pathology, University of Genoa, Via De Toni 14, 16132 Genoa, Italy.
    • ,
  • Luca Mastracci, MD

      Affiliations

    • Department of Anatomic Pathology, University of Genoa, Genoa, Italy
    • ,
  • Robert Riddell, MD

      Affiliations

    • Department of Pathology, Mount Sinai Hospital, Toronto, Canada
    • ,
  • Kaiyo Takubo, MD

      Affiliations

    • Department of Clinical Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    • ,
  • Michael Vieth, MD

      Affiliations

    • Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany
    • ,
  • Lisa Yerian, MD

      Affiliations

    • Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH
    • ,
  • Prateek Sharma, MD

      Affiliations

    • Division of Gastroenterology and Hepatology, University of Kansas School of Medicine, Kansas City, KS, USA
    • ,
  • Paula Fernström, MSc

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • Magnus Ruth, MD

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden

Received 26 March 2009 ,Revised 18 July 2009 ,Accepted 23 July 2009.

References 

  1. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456
  2. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, et al. The Montreal definition and classification of gastro-esophageal reflux disease (GERD)—a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920
  3. Stanghellini V, Cogliandro R, Cogliandro L, et al. Unsolved problems in the management of patients with gastro-oesophageal reflux disease. Dig Liver Dis. 2003;35:843–848
  4. Voutilainen M, Sipponen P, Mecklin JP, et al. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion. 2000;61:6–13
  5. Zagari RM, Pozzato P, Nicolini G, et al. Prevalence of asymptomatic endoscopic lesions of the upper gastrointestinal tract. Preliminary results of The Loiano-Monghidoro population study. Gastroenterology. 2002;122:A208
  6. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40:275–285
  7. Wiener GJ, Morgan TM, Copper JB, et al. Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci. 1988;33:1127–1133
  8. Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol. 2003;98:740–749
  9. Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. Gastroenterology. 1970;58:163–174
  10. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management—the Genval Workshop Report. Gut. 1999;44(Suppl 2):S1–16
  11. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007;5:4-16 e1.
  12. Bove M, Vieth M, Dombrowski F, et al. Acid challenge to the human oesophageal mucosa: effects on epithelial architecture in health and disease. Dig Dis Sci. 2005;50:1488–1496
  13. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol. 2005;100:537–542
  14. Stolte M, Vieth M, Schmitz JM, et al. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol. 2000;35:1125–1130
  15. Vieth M, Kulig M, Leodolter A, et al. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther. 2006;23:313–319
  16. Vieth M, Fiocca R, Haringsma J, et al. Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesions. Dig Dis. 2004;22:208–212
  17. Vieth M, Peitz U, Labenz J, et al. What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa. Dig Dis. 2004;22:196–201
  18. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic anti-reflux surgery to esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 2008;57:1207–1213
  19. Haas M. The reliability of reliability. J Manipulative Physiol Ther. 1991;14:199–208
  20. Edebo A, Vieth M, Tam W, et al. Radial and axial distribution histological markers of epithelial damage in reflux disease. Is there an effect of therapy and correlation to the localisation of mucosal breaks. Gut. 2004;53:A117
  21. Fletcher J, Wirz A, Henry E, et al. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut. 2004;53:168–173
  22. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol. 1990;43:551–558
  23. el-Zimaity HM, Graham DY, al-Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol. 1996;27:35–41
  24. Offerhaus GJ, Price AB, Haot J, et al. Observer agreement on the grading of gastric atrophy. Histopathology. 1999;34:320–325
  25. Gronbaek K, Christensen PB, Hamilton-Dutoit S, et al. Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. J Viral Hepat. 2002;9:443–449
  26. Guarner J, Herrera-Goepfert R, Mohar A, et al. Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol. 1999;30:1431–1434
  27. Zentilin P, Savarino V, Mastracci L, et al. Reassessment of the diagnostic value of histology in patients with GORD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005;100:2299–2306
  28. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378
  29. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002;16:1249–1259

☆ AstraZeneca R&D, Mölndal, Sweden, provided economic support for travel arrangements, logistics, biopsy specimens/photos and statistical analyses.

☆☆ Conflicts of interest: None declared: R. Fiocca, L. Mastracci, R. Riddell, K. Takubo, M. Vieth, L. Yerian, P. Sharma. Employees of AstraZeneca: P. Fernström, M. Ruth.

PII: S0046-8177(09)00278-0

doi: 10.1016/j.humpath.2009.07.016

Human Pathology
Volume 41, Issue 2 , Pages 223-231 , February 2010

Article Tools

* Image Usage & Resolution